Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Preemptive Fast Withdrawal of Immunosuppression and Donor Lymphocyte Infusions for Achieving Complete Donor Chimerism Following Allogeneic Transplant for Pediatric Hematologic Malignancies

NCT01036009 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT01036009
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01036009 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Preemptive Fast Withdrawal of Immunosuppression and Donor Lymphocyte Infusions for Achieving Complete Donor Chimerism Following Allogeneic Transplant for Pediatric Hematologic Malignancies
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2009
Completion date
July 31, 2015
Enrollment
43 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, biphenotypic leukemia, bone marrow clonal malformations, chronic myelogenous leukemia, juvenile myelomonocytic leukemia, monosomy 7, myelodysplastic syndromes, pre-leukemic syndromes